Accessed October 23, 2023
Who Might Benefit Zepbound may be the strongest option for Hashimoto's patients who: Have a BMI of 30 or greater, or 27 or greater with at least one weight-related condition Haven't achieved meaningful weight loss with other medications or lifestyle interventions Have significant insulin resistance or prediabetes alongside their Hashimoto's Carry improved inflammatory markers (hsCRP above 3.0 mg/L) Want the maximum weight loss potential currently available in a single medication Don't have a history of medullary thyroid cancer or MEN2 Zepbound is FDA-approved for chronic weight management, so Hashimoto's patients who meet the BMI criteria have a recognized pathway to treatment
B12 deficiency can mimic GLP-1 side effects like fatigue and brain fog, making it difficult to distinguish medication effects from nutritional deficiency without testing
Every patient's situation is different, which is why discussing your full vein history with a specialist matters

Premium weight loss without the premium cost In stock: Ships free in 1-3 days, if prescribed Undergoes extensive quality checks and made in USA pharmacies Pricing Breakdown: $199 with code: DAD100 Same price no matter the dose Cancel anytime Free shipping Whats Included: Monthly dose of medication Initial doctor consult Personalized treatment Unlimited clinician support Pricing/Dose: $449 with code: DAD150 Enter code at checkout after qualification form Personalized doses that increase over time Whats Included: 3 months of medication Initial doctor consult Personalized treatment Unlimited clinician support Whats Included: Medication Initial health consult Personalized treatment Support from board-certified clinicians Whats Included: Medication Initial health consult Personalized treatment Unlimited provider messaging Whats Included: Medication Initial health consult Personalized treatment Unlimited provider messaging Dads on compounded GLP-1 have reported losing up to 10+ lbs in the first month and seeing significant weight loss over timeall with support from licensed providers

Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges